6314-14-3

Usage

Uses

Used in Pharmaceutical Industry:
6-Hydroxy-2-(methylsulfanyl)-4-pyrimidinecarboxylic acid is used as a potential therapeutic agent for the development of new drugs and treatments. Its unique chemical structure, including the hydroxyl and methylsulfanyl groups, may provide valuable properties for medicinal chemistry applications.

InChI:InChI=1/C6H6N2O3S/c1-12-6-7-3(5(10)11)2-4(9)8-6/h2H,1H3,(H,10,11)(H,7,8,9)

Upstream product

• 69764-01-8 2-methylsulfanyl-6-oxo-1,6-dihydro-pyrimidine-4-carbaldehyde 
• 2986-19-8 carbamimidothioic acid methyl ester 
• 98807-33-1 4-Methyl-benzoic acid (3aR,4R,6R,6aR)-6-(4-benzoylamino-2-oxo-2H-pyrimidin-1-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethyl ester 
• 74-83-9 methyl bromide 
• 102880-47-7 6-diethoxymethyl-2-methylsulfanyl-3H-pyrimidin-4-one 
• 14527-26-5 2-methylisothiourea sulphate 
• 40876-98-0 sodium 1,4-diethoxy-1,4-dioxobut-2-en-2-olate 
• 108-56-5 diethyl oxaloacetate 

Downstream Products

• 65-86-1 orotic acid 
• 6153-44-2 methyl orotate 
• 1747-53-1 ethyl orotate 
• 769-97-1 Orotsaeure-amid 
• 200000-17-5 6-chloro-2-(methylthio)pyrimidine-4-carbonyl chloride 

Relevant academic research and scientific papers

APOPTOSIS INHIBITORS

The invention provides compounds that are inhibitors or covalent modifiers of succinate dehydrogenase subunit B (SDHB) and/or inhibitors of apoptosis, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition.

NOVEL DGAT2 INHIBITORS

The present invention provides compounds of the Formula below: [Formula should be inserted here] Where A, X, R, and R2-R3 are as described herein; methods of treating patients for hypertriglyceridemia and cardiovascular disease including dyslipidemia and

Modulators of ATP-binding cassette transporters

4-amido-pyrimidine compounds, derivatives and compositions thereof, and synthetic methods described herein are useful for modulating ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regula